LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_000314.8:c.634+1_634+3del
PTEN
· NP_000305.3:p.?
· NM_000314.8
GRCh37: chr10:89712015 CAGT>C
·
GRCh38: chr10:87952258 CAGT>C
Gene:
PTEN
Transcript:
NM_000314.8
Final call
Likely Pathogenic
PVS1 very strong
PM2 supporting
Variant details
Gene
PTEN
Transcript
NM_000314.8
Protein
NP_000305.3:p.?
gnomAD AF
ClinVar
OncoKB
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PVS1 very strong: the exon 6 donor disruption causes a frameshifting exon skip predicted to undergo nonsense-mediated decay.
2
PM2 supporting: the variant is absent from gnomAD v2.1 and v4.1.
Final determination:
The PTEN Expert Panel Version 3.2 Rule20 is satisfied by one very strong pathogenic criterion and one supporting pathogenic criterion, producing a Likely Pathogenic classification.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | Met | Met, very strong: exon 6 donor disruption causes a 142-nucleotide frameshifting skip 5' of p.D375 in NM_000314.8, matching the VCEP's full PVS1 path. |
cspec
vcep_pvs1_decisiontree_pten
pvs1_variant_assessment
PMID:28677221
PMID:16014636
|
| PS1 | Not assessed | Not assessed: a nearby c.634+1G>C splice variant causes exon 6 skipping, but pathogenic status and a comparable in-silico result are unavailable. |
cspec
PMID:28677221
|
| PS2 | Not assessed | Not assessed: no documented proband, confirmed maternity and paternity, or family-history information establishes a de novo observation. |
cspec
|
| PS3 | Not assessed | Not assessed: no damaging RNA, mini-gene, or other splicing-assay result is available for this canonical splice-site deletion. |
vcep_mmc2
PMID:29706350
cspec
|
| PS4 | Not assessed | Not assessed: no affected-case counts, matched controls, or proband phenotype-specificity scores are available to evaluate the PTEN PS4 rule. |
cspec
PMID:28677221
PMID:23470840
PMID:39316756
PMID:16014636
gnomad_v2
gnomad_v4
|
| PM1 | N/A | Not applicable: the canonical splice-site deletion has protein consequence p.? and no amino-acid residue to compare with the PM1 intervals 90-94, 123-130, and 166-168. |
cspec
|
| PM2 | Met | Met, supporting: the variant is absent from gnomAD v2.1 and v4.1, satisfying the VCEP PM2 requirement of less than 0.00001 (0.001%) allele frequency. |
cspec
gnomad_v2
gnomad_v4
|
| PM3 | N/A | Not applicable: the PTEN VCEP specification explicitly designates PM3 as not applicable. |
cspec
|
| PM4 | N/A | Not applicable: the variant is a frameshifting canonical splice disruption, not an in-frame indel affecting a catalytic motif or a stop-loss extension. |
cspec
|
| PM5 | N/A | Not applicable: PM5 requires a missense change at an amino-acid residue, whereas this variant is a canonical splice-site deletion with protein consequence p.?. |
cspec
|
| PM6 | Not assessed | Not assessed: no assumed de novo proband observation with parental-confirmation status and no-family-history evidence is documented. |
cspec
|
| PP1 | Not assessed | Not assessed: no affected-family co-segregation observations or meioses are documented against the VCEP minimum of 3 meioses. |
cspec
|
| PP2 | N/A | Not applicable: PP2 is restricted to missense variants, while this variant is a canonical splice-site deletion with protein consequence p.?. |
cspec
|
| PP3 | Not assessed | Not assessed: SpliceAI max delta 0.99 supports impact, but the VCEP requires concordant VarSeak class 4 or 5 and no VarSeak result is available. |
cspec
spliceai
|
| PP4 | N/A | Not applicable: the PTEN VCEP incorporates phenotype specificity into PS4 Use 2 and explicitly excludes separate PP4 application. |
cspec
|
| PP5 | N/A | Not applicable: the PTEN VCEP explicitly prohibits PP5 use under its governing specification. |
cspec
|
| BA1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, rather than exceeding the VCEP BA1 threshold of 0.00056 (0.056%). |
cspec
gnomad_v2
gnomad_v4
|
| BS1 | Not met | Not met: the variant is absent from gnomAD v2.1 and v4.1, with no allele frequency in either VCEP BS1 interval of 0.0000043 to 0.00056. |
cspec
gnomad_v2
gnomad_v4
|
| BS2 | Not met | Not met: gnomAD v2.1 and v4.1 report no variant observations, so there is no qualifying homozygous observation in a healthy or PHTS-unaffected individual. |
cspec
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no RNA, mini-gene, or other splicing assay demonstrates that this canonical splice-site deletion has no splicing impact. |
vcep_mmc2
PMID:29706350
cspec
|
| BS4 | Not assessed | Not assessed: no affected relatives lacking the variant or family-level non-segregation observations are documented. |
cspec
|
| BP1 | N/A | Not applicable: the ClinGen PTEN VCEP marks BP1 as Not Applicable. |
cspec
|
| BP2 | Not assessed | Not assessed: no qualifying trans observation or at least three cis/phase-unknown observations with different pathogenic PTEN variants are documented. |
cspec
|
| BP3 | N/A | Not applicable: the PTEN VCEP explicitly marks BP3 as Not Applicable, and this splice-site loss-of-function variant is outside that criterion. |
cspec
|
| BP4 | Not met | Not met: SpliceAI max delta 0.99 exceeds the VCEP BP4 benign range of 0-0.2, and VarSeak concordance is unavailable. |
cspec
spliceai
|
| BP5 | Not assessed | Not assessed: no two qualifying cases with an alternate highly penetrant molecular diagnosis and non-overlapping PTEN history are documented. |
cspec
|
| BP6 | N/A | Not applicable: the PTEN VCEP explicitly prohibits BP6 use under its governing specification. |
cspec
|
| BP7 | N/A | Not applicable: the intronic deletion is at the canonical +1 splice donor, not at or beyond the VCEP BP7 boundary of +7/-21. |
cspec
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.